InVivo Therapeutics Announces Late-Breaking Oral Presentation at the 2016 Congress of Neurological Surgeons
Annual Meeting
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Michael Fehlings, M.D., Ph.D., Director of the Spinal
Program at the Krembil Neuroscience Centre of Toronto Western Hospital and a Professor of Neurosurgery at the University of
Toronto, will give a late-breaking oral presentation titled “Clinical-Pathological Assessment of Severe (AIS A) Traumatic Acute
Thoracic Spinal Cord Injury: Post-Durotomy/Myelotomy Observations from the INSPIRE Trial” at the 2016 Congress of Neurological
Surgeons (CNS) Annual Meeting on September 28, 2016. The abstract was one of the top three late-breaking abstracts chosen for an
oral presentation.
“INSPIRE has provided new insights into acute spinal cord injury pathology, allowing for the application of the Neuro-Spinal
ScaffoldTM as a potential new treatment modality for complete spinal cord injury. I’m looking forward to
sharing the findings with the neurosurgical community,” Dr. Fehlings said.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said “We are delighted that important scientific observations being
made in the INSPIRE study were selected for late-breaking oral presentation at a prestigious neurosurgical conference and that one
of the leaders in the field of spinal cord injury treatment and research is making the presentation.”
As previously announced, Nicholas Theodore, M.D., Director of the John Hopkins Neurosurgical Spine Center, will be giving an
oral platform presentation; Robert Heary, M.D., Director of the Spine Center at Rutgers New Jersey Medical School will be giving a
poster presentation; and the company will have a steering committee meeting and exhibitor booth.
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the
decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity
formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal
Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated
in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord
injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on
treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D.,
Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who
now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered
in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
InVivo Therapeutics
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005156/en/